Corneal Epithelial Defects Following Vitrectomy Surgery Using Hand-Held, Sew-On, and Noncontact Viewing Lenses

Virata,; Ja, Kylstra; Ht, Singh

doi:10.1097/00006982-199907000-00003

Cited by 32 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In diabetic patients, this is to be carried out with utmost caution as it can result in persistent nonhealing epithelial defect in the postoperative period because of neuropathy and poor adhesion between corneal epithelial layers . The incidence of corneal epithelial defects has decreased dramatically after the introduction of noncontact wide‐angle viewing system …”

Section: Intraoperative Complications and Their Preventionmentioning

confidence: 99%

Surgical treatment for diabetic vitreoretinal diseases: a review

Sharma

Fong

Lai³

et al. 2016

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Over the past four decades, advancements in surgical instrumentations and techniques have significantly improved the postoperative anatomical and visual outcomes of patients with various diabetic vitreoretinal diseases. In particular, surgical interventions for previously serious and untreatable blinding proliferative diabetic retinopathy can now be performed, with much better results. The advents of micro incisional vitrectomy system with better visualization system like binocular indirect ophthalmomicroscope and stateof-the-art instrumentation revolutionized the era of diabetic vitrectomy. High-speed vitrectors, finer instruments, chromo-assisted vitrectomy and use of antivascular endothelial growth factors not only change the paradigm but also help achieve much better outcome after diabetic vitrectomies. In this review, we will discuss and summarize the indications, surgical considerations, surgical techniques, potential complications and outcomes of vitreoretinal surgery for diabetic eye diseases.

show abstract

Section: Intraoperative Complications and Their Preventionmentioning

confidence: 99%

Surgical treatment for diabetic vitreoretinal diseases: a review

Sharma

Fong

Lai³

et al. 2016

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…53 Elevation in intraocular pressure commonly occurs secondary to trabecular meshwork obstruction by erythrocytes and/or the effects of intraocular gas tamponade. Under these circumstances the IOP can be usually readily controlled by medical treatment.…”

Section: Complications After Vitrectomy For Vhmentioning

confidence: 99%

Current Management of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy

Annan

Carvounis

2014

International Ophthalmology Clinics

View full text Add to dashboard Cite

Diabetic vitreous hemorrhage secondary to proliferative diabetic retinopathy is a cause of severe vision loss in diabetic patients. Laser photocoagulation remains the primary treatment when the view allows. Intravitreous anti-VEGF injections do not appear to have a role as primary treatment but may have an invaluable role as adjuvant to surgery. Pars plana vitrectomy with endolaser panretinal photocoagulation remains the procedure of choice for non-clearing vitreous hemorrhage. The vast majority of patients with vision of 5/200 or less due to diabetic vitreous hemorrhage do not clear spontaneously even after 1 year. With improvements in surgical techniques leading to better outcomes, fewer complications, less discomfort and a faster recovery time it is reasonable to operate on such patients sooner than the 3–4 months that had been generally accepted in the past, if there has been no significant spontaneous improvement.

show abstract

“…In the U.S., 250,000 vitrectomy surgeries are performed annually, 24 with an estimated 25%–53% performed on diabetic patients. The frequency of epithelial debridement during diabetic vitrectomy is estimated at 17.4%.…”

Section: Characteristics Of Persistent Corneal Epithelial Defectsmentioning

confidence: 99%

Novel Therapy to Treat Corneal Epithelial Defects: A Hypothesis with Growth Hormone

et al. 2015

View full text Add to dashboard Cite

Impaired corneal wound healing that occurs with ocular surface disease, trauma, systemic disease, or surgical intervention can lead to persistent corneal epithelial defects (PCED), which result in corneal scarring, ulceration, opacification, corneal neovascularization, and, ultimately, visual compromise and vision loss. The current standard of care can include lubricants, ointments, bandage lenses, amniotic membranes, autologous serum eye drops, and corneal transplants. Various inherent problems exist with application and administration of these treatments, which often may not result in a completely healed surface. A topically applicable compound capable of promoting corneal epithelial cell proliferation and/or migration would be ideal to accelerate healing. We hypothesize that human growth hormone (HGH) is such a compound. In a recent study, HGH was shown to activate signal transducer and activators of transcription-5 (STAT5) signaling and promote corneal wound healing by enhancing corneal epithelial migration in a co-culture system of corneal epithelial cells and fibroblasts. These effects require an intact communication between corneal epithelia and fibroblasts. Further, HGH promotes corneal wound healing in a rabbit debridement model, thus demonstrating the effectiveness of HGH in vivo as well. In conclusion, HGH may represent an exciting and effective topical therapeutic to promote corneal wound healing.

show abstract

Corneal Epithelial Defects Following Vitrectomy Surgery Using Hand-Held, Sew-On, and Noncontact Viewing Lenses

Cited by 32 publications

References 0 publications

Surgical treatment for diabetic vitreoretinal diseases: a review

Surgical treatment for diabetic vitreoretinal diseases: a review

Current Management of Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy

Novel Therapy to Treat Corneal Epithelial Defects: A Hypothesis with Growth Hormone

Contact Info

Product

Resources

About